Slide Left Slide Right
Accelmed Partners invests in private and public HealthTech companies in the US and Europe
Accelmed Partners merges mature HealthTech businesses with promising innovative companies, creating significant revenue growth and returns
Accelmed Partners’ Buyout and Growth strategies have proven to provide high value to investors and companies
Accelmed Ventures invests in innovative HealthTech companies that are focused on diagnosis and management of conditions with significant unmet medical need
Accelmed Partners invests in private and public HealthTech companies in the US and Europe
Accelmed Partners merges mature HealthTech businesses with promising innovative companies, creating significant revenue growth and returns
Accelmed Partners’ Buyout and Growth strategies have proven to provide high value to investors and companies
Accelmed Ventures invests in innovative HealthTech companies that are focused on diagnosis and management of conditions with significant unmet medical need
Accelmed Partners invests in private and public HealthTech companies in the US and Europe
Accelmed Partners merges mature HealthTech businesses with promising innovative companies, creating significant revenue growth and returns
Accelmed Partners’ Buyout and Growth strategies have proven to provide high value to investors and companies
Accelmed Ventures invests in innovative HealthTech companies that are focused on diagnosis and management of conditions with significant unmet medical need
Accelmed Partners invests in private and public HealthTech companies in the US and Europe
Accelmed Partners merges mature HealthTech businesses with promising innovative companies, creating significant revenue growth and returns
Accelmed Partners’ Buyout and Growth strategies have proven to provide high value to investors and companies
Accelmed Ventures invests in innovative HealthTech companies that are focused on diagnosis and management of conditions with significant unmet medical need
 
 
 
 
 

Investing in mature HealthTech companies 

Accelmed is a global group of funds investing in HealthTech companies (medical device, diagnostics and digital health) across all stages. We currently invest through two separate arms:

  • Accelmed Partners – a US based lower market private equity HealthTech fund, focused on Buyout and Growth Investments in commercial HealthTech (>$10M LTM) companies.

  • Accelmed Ventures – an Israel based Venture fund, focused on pre-commercialization HealthTech Opportunities.

 

 

 

 

 

 
 
 
 
 

Accelmed Partners: Buyout Strategy

 

Acquiring commercial HealthTech companies and fostering significant value creation by supporting management teams, driving innovation, providing growth capital and potentially integrating innovative add-on technologies, largely from Israel.

Accelmed Partners brings its expertise in HealthTech and its presence in the US and Israel to the Buyout model. With a broad geographic lens and deep experience in the field, Accelmed is uniquely positioned to find and drive value for portfolio companies.

We are looking to partner with companies that have significant commercial infrastructure (>$20M LTM Revenue), an existing customer base and established sales channels, but that may lack new products and growth, and are interested in scaling and growing their businesses by gaining access to innovative products and growth capital.

 

Accelmed Partners targets equity investments of $10-50M per transaction.

 

Accelmed_Growth_Partners

 

The proceeds of our investments are used for both organic and potentially inorganic growth through the acquisition and integration of innovative market ready technologies identified and selected by Accelmed and the platform company management.

 

 

Accelmed Partners: Structured Growth Strategy

 

Assist commercially proven companies to achieve their potential

Accelmed Partners’ seasoned team helps companies address and solve their scaling and execution challenges.

We are looking to invest in mature HealthTech companies with proven commercial traction (>$10M of LTM Revenue) in need of growth capital and Accelmed’s support to get to liquidity.

We invest in de-risked commercial growth stage companies that have resolved: development/technical risk, clinical risk, regulatory risk and reimbursement risk

  • Our primary focus is on reducing execution risk. We partner with excellent management teams that can benefit from AGP’s vast experience in the HealthTech industry.  

 

 

Accelmed Ventures Strategy

 

Create successful, high value medical device and digital health companies by identifying strong teams, large markets and novel ideas.

We focus on:

  • Early stage innovation aiming to resolve key unmet medical needs

  • Pre/Early revenue companies – invest in opportunities that will mature 5 years from investment

  • Asia focus – seek investment syndication from Asia that will create more value for Israeli technologies. 

 

Case Studies

Cogentix 

The Buyout/Platform Model is best illustrated through Accelmed Growth Partner’s investment in Cogentix (NASDAQ: CGNT). Cogentix offered three legacy product lines developed more than a decade ago and had sales of approximately $40M which were basically flat. It faced competition from larger players, such as Medtronic and had a significant debt ($29M).

Accelmed invested $25M in Cogentix in November 2016 and gained control over the company together with Mr. Lew Pell who converted his $29M of debt into equity. Dr. Uri Geiger became the Chairman of the company and a new CEO (Darrin Hammers) was nominated. In a little more than a year, Accelmed focused the company around its Urology product line, transforming the company into a dynamic, high growth company (18% annual growth) through both organic (investment in S&M) and in-organic (three add-on transactions) activities. The company’s share price has more than tripled in the 15 months since the announcement of the Accelmed investment. In March 2018 the company signed an agreement to be sold to Laborie for $240M in cash.

 

 

Strata Skin

In June 2018, Accelmed acquired control of Strata Skin (NASDAQ: SSKN), a commercial dermatology platform with sales exceeding $30, at an EV of $29M.

With new management, Accelmed led the company from flat sales and significant losses to over 15% growth and cash generation in Q1-2019, resulting in a 250% appreciation in the stock price over that period.

 

 
 
 
 
 
 
 
 

.

+
Dr. Uri Geiger PhD
Founder and Managing Partner
 
+
Mori Arkin
Founding Partner
 
 

AGP II Team

+
Lior Shav
Partner
 
+
Dr. Rafael Torgovicky MD
Partner
 
+
Dr. Guy Ohad MD
Partner & Chief Medical Officer
 
+
Dr. Irit Yaniv MD
Operating Partner
 
+
Ilan Ben Oren
Operating Partner & CTO
 
+
Nir Gilad
Investment Manager
 
 

Accelmed Ventures Team

+
Dr. Irit Yaniv MD
Managing Partner
 
+
Amir Blatt
Partner
 
 

Executives Network

 

Accelmed enjoys close collaboration with a network of seasoned executives who have built, led and sold companies for billions of dollars. These executives assist Accelmed in identifying and analyzing potential opportunities and may serve in key leadership roles in future platform companies.

 
 
 
 
 
 
 

Buyout

+
Keystone Dental
Keystone Dental
 
+
Strata Skin Sciences
Strata Skin Sciences
 
+
Exalenz
Exalenz
 
 

Growth

+
EndoGastric Solutions
EndoGastric Solutions
 
 

Targeted Innovation

+
Corvia
Corvia
 
+
Valcare Medical
Valcare Medical
 
+
Digma
Digma
 
+
SoniVie
SoniVie
 
+
Cynerio
Cynerio
 
 

Incubator

+
Eximo Medical
Eximo Medical
 
+
Memic
Memic
 
+
NitiNotes
NitiNotes
 
+
ReVamp
ReVamp
 
 

Venture Capital

+
CartiHeal
CartiHeal
 
+
EndoSpan
EndoSpan
 
+
Nitiloop
Nitiloop
 
+
Pi-Cardia
Pi-Cardia
 
+
Tailormed
Tailormed
 
 

Sold Companies

+
Cogentix
Cogentix
 
+
Endochoice
Endochoice
 
+
Ophthalmic Imaging Systems
Ophthalmic Imaging Systems
 
+
Volcano
Volcano
 
 
Contact

Accelmed Partners:
400 Madison Avenue, Suite 9B
New York, NY, 10017
Tel: +1-212-554-4601

Accelmed Venture Partners:
6 Hachoshlim St. 6th floor
Herzliya Pituach, 46120
Tel: +972-9-7885599

Email: info@accelmed.com